MENU
+Compare
EDSA
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$1.70
Change
+$0.01 (+0.59%)
Capitalization
5.9M

EDSA Edesa Biotech Forecast, Technical & Fundamental Analysis

a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs.

Industry Biotechnology
EDSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EDSA with price predictions
Jan 14, 2025

EDSA in -10.43% downward trend, falling for three consecutive days on January 14, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EDSA declined for three days, in of 325 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EDSA as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDSA advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .

EDSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EDSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.975) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). EDSA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (263.573).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
EDSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

EDSA is expected to report earnings to rise 56.70% to -15 cents per share on December 13

Edesa Biotech EDSA Stock Earnings Reports
Q3'23
Est.
$-0.16
Q2'23
Beat
by $0.06
Q1'23
Est.
$-0.12
Q4'22
Beat
by $0.05
Q3'22
Beat
by $0.03
The last earnings report on August 11 showed earnings per share of -10 cents, beating the estimate of -15 cents. With 3.86K shares outstanding, the current market capitalization sits at 5.90M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Spy Court
Phone
+1 289 800-9600
Employees
16
Web
https://www.edesabiotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

EDSA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EDSA has been loosely correlated with YECO. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EDSA jumps, then YECO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDSA
1D Price
Change %
EDSA100%
+0.60%
YECO - EDSA
36%
Loosely correlated
N/A
ETNB - EDSA
30%
Poorly correlated
+3.53%
PBYI - EDSA
25%
Poorly correlated
-1.66%
IPSC - EDSA
24%
Poorly correlated
+0.45%
ACHFF - EDSA
24%
Poorly correlated
-1.88%
More